Well, Lightpath technologies, ticker LPTH, seemed to have hit the jackpot on this one. As manufacturers of optical components, lenses and thermal imaging equipment, the company ticks all the boxes when it comes to the future of mass diagnosis. Their only limitation lies with their manufacturing and production capacity, which can take a lot of time, but their CEO Sam Rubin is confident about the future, saying; “We have a strong pipeline of opportunities. Some of them are in the quoting process, many of them in the design process in which we work very closely with the customer, and some of them in the prototyping process. We believe that we have some significant wins coming down the road.” Mr Rubin and Lightpath definitely make our list.